PDF(Pubmed)
Abstract：
BACKGROUND: Coronavirus disease 2019 (COVID-19) has spread rapidly, giving rise to a pandemic, causing significant morbidity and mortality. In this context, many vaccines have emerged to try to deal with this disease.
OBJECTIVE: To review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes.
METHODS: We carried out a review through bibliographic searches in PubMed.
RESULTS: We found 86 articles, including 13 809 patients with a wide spectrum of neurological manifestations temporally associated with COVID-19 vaccination. Most occurred in women (63.89%), with a median age of 50 years. The most frequently reported adverse events were Bell\'s palsy 4936/13 809 (35.7%), headache (4067/13 809), cerebrovascular events 2412/13 809 (17.47%), Guillain-Barré syndrome 868/13 809 (6.28%), central nervous system demyelination 258/13 809 (1.86%) and functional neurological disorder 398/13 809 (2.88%). Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S).
CONCLUSIONS: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. However, it is necessary for health professionals to be familiar with these events, facilitating their early diagnosis and treatment. Large controlled epidemiological studies are necessary to establish a possible causal relationship between vaccination against COVID-19 and neurological adverse events.
OBJECTIVE: To review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes.
METHODS: We carried out a review through bibliographic searches in PubMed.
RESULTS: We found 86 articles, including 13 809 patients with a wide spectrum of neurological manifestations temporally associated with COVID-19 vaccination. Most occurred in women (63.89%), with a median age of 50 years. The most frequently reported adverse events were Bell\'s palsy 4936/13 809 (35.7%), headache (4067/13 809), cerebrovascular events 2412/13 809 (17.47%), Guillain-Barré syndrome 868/13 809 (6.28%), central nervous system demyelination 258/13 809 (1.86%) and functional neurological disorder 398/13 809 (2.88%). Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S).
CONCLUSIONS: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. However, it is necessary for health professionals to be familiar with these events, facilitating their early diagnosis and treatment. Large controlled epidemiological studies are necessary to establish a possible causal relationship between vaccination against COVID-19 and neurological adverse events.
摘要：
背景：2019年冠状病毒病（COVID-19）迅速蔓延，引起大流行，导致显著的发病率和死亡率。在这种情况下，已经出现了许多疫苗来尝试治疗这种疾病。
目的：。回顾报告的应用COVID-19疫苗后的神经系统表现病例，描述临床，分析和神经影像学发现以及健康结果。
方法：我们通过PubMed中的书目搜索进行了回顾。
结果：我们发现了86篇文章，包括13,809例患者，这些患者具有与COVID-19疫苗接种暂时相关的广泛神经系统表现。大多数发生在女性（63.89%），平均年龄为50岁。最常报告的不良事件是贝尔麻痹4936/13809（35.7%），头痛（4067/13809），脑血管事件2412/13809（17.47%），格林-巴利综合征868/13809（6.28%），中枢神经系统脱髓鞘258/13809（1.86%）和功能性神经系统疾病398/13809（2.88%）。大多数已发表的病例与辉瑞疫苗（BNT162b2）暂时相关，其次是阿斯利康疫苗（ChAdOX1nCoV-19）。
结论：根据现有数据，无法确定这些不良事件与COVID-19疫苗之间的因果关系，也不能计算这些疾病的出现频率。然而,卫生专业人员必须熟悉这些事件，促进其早期诊断和治疗。大型对照流行病学研究对于确定COVID-19疫苗接种与神经系统不良事件之间可能的因果关系是必要的。
目的：。回顾报告的应用COVID-19疫苗后的神经系统表现病例，描述临床，分析和神经影像学发现以及健康结果。
方法：我们通过PubMed中的书目搜索进行了回顾。
结果：我们发现了86篇文章，包括13,809例患者，这些患者具有与COVID-19疫苗接种暂时相关的广泛神经系统表现。大多数发生在女性（63.89%），平均年龄为50岁。最常报告的不良事件是贝尔麻痹4936/13809（35.7%），头痛（4067/13809），脑血管事件2412/13809（17.47%），格林-巴利综合征868/13809（6.28%），中枢神经系统脱髓鞘258/13809（1.86%）和功能性神经系统疾病398/13809（2.88%）。大多数已发表的病例与辉瑞疫苗（BNT162b2）暂时相关，其次是阿斯利康疫苗（ChAdOX1nCoV-19）。
结论：根据现有数据，无法确定这些不良事件与COVID-19疫苗之间的因果关系，也不能计算这些疾病的出现频率。然而,卫生专业人员必须熟悉这些事件，促进其早期诊断和治疗。大型对照流行病学研究对于确定COVID-19疫苗接种与神经系统不良事件之间可能的因果关系是必要的。
